Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Research Grant, 2016
    LRRK2 Function in Immunity

    Study Rationale:
    LRRK2 is expressed in immune cells but its function in these cells is unknown. It is also not known whether mutations (such as G2019S) in LRRK2 that cause familial (inherited)...

  • LRRK2 Therapeutic and Safety Initiative, 2016
    Evaluation of LRRK2 Inhibition in a Pre-clinical Model of Parkinson's Disease

    Study Rationale:

    The most common genetic cause of Parkinson's disease (PD) is mutations in the LRRK2 gene. Variations in the LRRK2 gene are associated with non-genetic PD as well. New drugs are being...

  • Improved Biomarkers and Clinical Outcome Measures, 2016
    Identification of Tear Biomarkers for Individuals with Parkinson's Disease

    Study Rationale:
    Prior to the appearance of classic movement abnormalities like tremor and slowness, those with Parkinson's suffer from non-motor symptoms, such as altered function of the...

  • Research Grant, 2016
    Study of Alpha-synuclein in the Dorsal Neostriatum

    Promising Outcomes of Original Grant:
    In February 2013, Luk et al. published in Science that administration of synthetic alpha-synuclein into pre-formed fibrils in pre-clinical models was sufficient to...

  • Therapeutic Pipeline Program, 2016
    Effect of HDAC Inhibition in Models of Parkinson's Disease

    Study Rationale:
    Numerous publications have linked the family of epigenetic enzymes known as HDACs (histone deactylases) to the underlying pathology of Parkinson's. This study will test the efficacy of...

  • Therapeutic Pipeline Program, 2016
    Cognitive Behavioral Therapy for Anxiety Disorders in Parkinson's Disease

    Study Rationale:
    Anxiety disorders occur in up to 35 percent of people with Parkinson's disease and can have a negative impact on gait, involuntary movements, motor fluctuations and quality of life...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.